.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Chubb
Medtronic
Daiichi Sankyo
Cantor Fitzgerald
Queensland Health
McKinsey
Merck
Boehringer Ingelheim
Argus Health

Generated: September 19, 2017

DrugPatentWatch Database Preview

Bristol Myers Squibb Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?

BRISTOL MYERS SQUIBB has seventy-seven approved drugs.

There are eighteen US patents protecting BRISTOL MYERS SQUIBB drugs and there have been two Paragraph IV challenges on BRISTOL MYERS SQUIBB drugs in the past three years.

There are four hundred and fifty-three patent family members on BRISTOL MYERS SQUIBB drugs in fifty-eight countries.

Summary for Applicant: Bristol Myers Squibb

Patents:18
Tradenames:66
Ingredients:58
NDAs:77
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-002Jun 28, 2006ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Bristol Myers Squibb
NEOMYCIN SULFATE
neomycin sulfate
TABLET;ORAL060365-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
COUMADIN
warfarin sodium
TABLET;ORAL009218-007Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
REMSED
promethazine hydrochloride
TABLET;ORAL083176-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-001Jun 28, 2006ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Bristol Myers Squibb
ETOPOPHOS PRESERVATIVE FREE
etoposide phosphate
INJECTABLE;INJECTION020906-001Feb 27, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
STILBESTROL
diethylstilbestrol
SUPPOSITORY;VAGINAL004056-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
COUMADIN
warfarin sodium
TABLET;ORAL009218-016Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
OXYCODONE 5/APAP 500
acetaminophen; oxycodone hydrochloride
TABLET;ORAL085911-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
STILBESTROL
diethylstilbestrol
INJECTABLE;INJECTION004056-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol Myers Squibb

Paragraph IV activity for BRISTOL MYERS SQUIBB drugs

Drugname Dosage Strength Tradename Submissiondate
apixaban
Tablets2.5 mg and 5 mg
ELIQUIS
12/28/2016
naloxone hydrochloride
Nasal Spray4 mg/spray
NARCAN
7/15/2016
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/17/2011
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/16/2011
dasatinib
Tablets20 mg, 50 mg, 70 mg and 100 mg
SPRYCEL
6/28/2010
entecavir
Tablets0.5 mg and 1 mg
BARACLUDE
6/14/2010
atazanavir sulfate
Capsules100 mg and 150 mg
REYATAZ
3/19/2010
atazanavir sulfate
Capsules200 mg
REYATAZ
2/16/2010
atazanavir sulfate
Capsules300 mg
REYATAZ
7/20/2009
efavirenz
Tablets600 mg
SUSTIVA
4/9/2009
pravastatin sodium
Tablets30 mg
PRAVACHOL
6/1/2005
didanosine
Delayed-release Capsules200 mg, 250 mg and 400 mg
VIDEX EC
6/1/2004

Non-Orange Book Patents for Bristol Myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,993,567Cyclic protein tyrosine kinase inhibitors► Subscribe
7,338,963Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
9,382,219Cyclic protein tyrosine kinase inhibitors► Subscribe
8,242,270Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors► Subscribe
6,995,172Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
6,673,810 Imidazo-heterobicycles as factor Xa inhibitors► Subscribe
8,188,120Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,371,761Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,691,846Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol Myers Squibb Drugs

Country Document Number Estimated Expiration
Germany122011100050► Subscribe
Norway993779► Subscribe
Serbia20050698► Subscribe
China100340559► Subscribe
Czech Republic296135► Subscribe
Serbia52291► Subscribe
TaiwanI351404► Subscribe
Australia2005304863► Subscribe
China1980909► Subscribe
Peru00422016► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
496Luxembourg► SubscribePRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
1261586/02Switzerland► SubscribePRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329
C0040Belgium► SubscribePRODUCT NAME: STAVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/009/001-009 19960509; FIRST REGISTRATION:
2107069/01Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
9 5017-2014Slovakia► SubscribePRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116
C0002Belgium► SubscribePRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
C/GB11/049United Kingdom► SubscribePRODUCT NAME: AZTREONAM LYSINE; REGISTERED: UK EU/1/09/543/001 20090921
C/GB00/027United Kingdom► SubscribePRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
0136011/03Switzerland► SubscribePRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417
5006-2008Slovakia► SubscribePRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
QuintilesIMS
Merck
Express Scripts
Daiichi Sankyo
Teva
Fuji
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot